AC187 is a modified salmon calcitonin (8-32) peptide widely used as an amylin receptor antagonist. It combines N-terminal acetylation with Asn30 and Tyr32 substitutions in the truncated salmon calcitonin scaffold.

These changes produce a ligand with a receptor profile distinct from both full-length salmon calcitonin and the unmodified sCT(8-32) fragment.

Product Information

Engineered from Salmon Calcitonin (8-32)

AC187 begins with the same N-terminally truncated calcitonin framework as sCT(8-32) but introduces additional terminal chemistry and sequence changes.

The N-terminus is acetylated, while the C-terminal region is altered to contain Asn30 and Tyr32. These modifications were developed to shift receptor pharmacology toward amylin antagonism.

Amylin Receptor Pharmacology

Classical binding experiments comparing AC187, sCT(8-32) and CGRP(8-37) found different rank orders of affinity depending on whether amylin or CGRP binding sites were examined.

This makes AC187 useful not only as a blocker but also as a comparative pharmacological probe for distinguishing closely related calcitonin-family receptor systems.

Experimental Considerations

Amylin receptors are formed through combinations of CALCR and receptor activity-modifying proteins, so apparent antagonist potency can depend on receptor composition.

We recommend documenting receptor/RAMP background when AC187 data are compared between systems.

Frequently Asked Questions

Is AC187 the same peptide as salmon calcitonin (8-32)?

No. AC187 is N-acetylated and contains additional Asn30 and Tyr32 substitutions.

Does AC187 contain a disulfide bond?

No. It begins at residue 8 and therefore lacks the N-terminal cysteine ring of full-length calcitonin.

Research Use Only.